Document is current
Any future updates will be listed below
-
Authors
Lorincz, Balazs
Vrablik, Michal
Murali, Ramanathan
Havrdova, Eva Kubala
Horakova, Dana
Krasensky, Jan
Vaneckova, Manuela
Uher, Tomas https://orcid.org/0000-0003-3160-9022
-
Funding
Funding for this research was provided by:
RVO VFN (64165)
- License Information
-
More Information
Article History
Received: 5 January 2024
Accepted: 16 October 2024
First Online: 25 October 2024
Declarations
:
: Balazs Lorincz received financial support for conference travel from Merck, Medtronic, Bayer and speaker honoraria from Sandoz. Manuela Vaneckova received speaker honoraria, consultant fees, and travel expenses from Biogen Idec, Novartis, Roche, Genzyme, and Teva, as well as support for research activities from Biogen Idec. Michal Vrablik reports fees for clinical trials, consultancy and presentations from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Mylan, Novartis, Novo Nordisk, Sanofi and Zentiva. Murali Ramanathan received research funding from the National Science Foundation, the Department of Defense, and the National Institutes of Health. Elizabeth C Jury is supported by grants from the Dunhill Medical Trust (RPGF1902\117) and NIHR UCLH Biomedical Research Centre grant BRC772/III/EJ/101350 and Fast Track grant F215. Jan Krasensky received financial support for research activities from Biogen Idec. Eva Kubala Havrdova received speaker honoraria and consultant fees from Biogen Idec, Merck Serono, Novartis, Genzyme, Teva, Actelion, and Receptos, as well as support for research activities from Biogen Idec and Merck Serono. Dana Horakova was supported by the Czech Ministry of Education project Progres Q27/LF1 and received compensation for travel, speaker honoraria, and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva, as well as support for research activities from Biogen Idec. R.A. received speaker honoraria, advisory board fees, research support or conference travel support from Biogen, Merck, Sanofi, Roche and Novartis. Tomas Uher received financial support for conference travel and honoraria from Biogen Idec, Novartis, Roche, Genzyme, and Merck Serono, as well as support for research activities from Biogen Idec and Sanofi.
: .
